Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53

被引:56
|
作者
Tang, H
Zhao, K
Pizzolato, JF
Fonarev, M
Langer, JC
Manfredi, JJ
机构
[1] CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA
[2] CUNY Mt Sinai Sch Med, Brookdale Ctr Mol & Dev Biol, New York, NY 10029 USA
关键词
D O I
10.1074/jbc.273.44.29156
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The tumor suppressor protein p53 has been implicated in the response of cells to DNA damage. Studies to date have demonstrated a role for p53 in the transcriptional activation of target genes in the cellular response to DNA damage that results in either growth arrest or apoptosis, In contrast, here is demonstrated a role for p53 in regulating the basal level of expression of the cyclin-dependent kinase inhibitor p21 in the absence of treatment with DNA-damasng agents. Wild-type p53-expressing MCF10F cells had detectable levels of p21 mRNA and protein, whereas the p53-negative Saos-2 cells did not. Saos-2 cells were infected with recombinant retrovirus to establish a proliferating pool of cells with a comparable constitutive level of expression of wild-type p53 protein to that seen in untreated MCF10F cells. Restoration of wild-type but not mutant p53 expression recovered a basal level of expression of p21 in these cells. Constitutive expression of luciferase reporter constructs containing the p21 promoter was inhibited by co-transfection with the human MDM2 protein or a dominant-negative p53 protein and was dependent on the presence of p53 response elements in the reporter constructs. Furthermore, p53 in nuclear extracts of untreated cells was capable of binding to DNA in a sequence-specific manner. These results implicate a role for p53 in regulating constitutive levels of expression of p21 and demonstrate that the p53 protein is capable of sequence-specific DNA binding and transcriptional activation in untreated, proliferating cells.
引用
收藏
页码:29156 / 29163
页数:8
相关论文
共 50 条
  • [31] The cyclin-dependent kinase inhibitor p21 limits murine mesangial proliferative glomerulonephritis
    Monkawa, T
    Pippin, J
    Yo, Y
    Kopp, JB
    Alpers, CE
    Shankland, SJ
    [J]. NEPHRON EXPERIMENTAL NEPHROLOGY, 2006, 102 (01): : E8 - E18
  • [32] Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor
    Rego, M. A.
    Harney, J. A.
    Mauro, M.
    Shen, M.
    Howlett, N. G.
    [J]. ONCOGENE, 2012, 31 (03) : 366 - 375
  • [33] MOLECULAR EXPRESSION OF CYCLIN DEPENDENT KINASE INHIBITOR (p21) IN CANINE TUMORS
    Manzoor, S.
    Saif, R.
    Sadia, H.
    Firyal, S.
    Tayyab, M.
    Mansha, M.
    Mahmood, A. K.
    Hashmi, A. S.
    Awan, A. R.
    Wasim, M.
    [J]. JOURNAL OF ANIMAL AND PLANT SCIENCES, 2019, 29 (04): : 1127 - 1134
  • [34] The cyclin-dependent kinase inhibitor p21 is regulated by RNA-binding protein PCBP4 via mRNA stability
    Scoumanne, Ariane
    Cho, Seong Jun
    Zhang, Jin
    Chen, Xinbin
    [J]. NUCLEIC ACIDS RESEARCH, 2011, 39 (01) : 213 - 224
  • [35] Frequent and heterogenous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma
    Clasen, S
    Schulz, WA
    Gerharz, CD
    Grimm, MO
    Christoph, F
    Schmitz-Dräger, BJ
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (04) : 515 - 521
  • [36] Frequent and heterogenous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma
    S Clasen
    WA Schulz
    C-D Gerharz
    M-O Grimm
    F Christoph
    BJ Schmitz-Dräger
    [J]. British Journal of Cancer, 1998, 77 : 515 - 521
  • [37] Ironing out the role of the cyclin-dependent kinase inhibitor, p21 in cancer: Novel iron chelating agents to target p21 expression and activity
    Moussa, Rayan S.
    Park, Kyung Chan
    Kovacevic, Zaklina
    Richardson, Des R.
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2019, 133 : 276 - 294
  • [38] IFN alpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells
    Hobeika, AC
    Subramaniam, PS
    Johnson, HM
    [J]. ONCOGENE, 1997, 14 (10) : 1165 - 1170
  • [39] p53, cyclin-dependent kinase and abnormal amplification of centrosomes
    Fukasawa, Kenji
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2008, 1786 (01): : 15 - 23
  • [40] Topographical association between the cyclin-dependent kinases inhibitor P21, p53 accumulation, and cellular proliferation in human atherosclerotic tissue
    Ihling, C
    Menzel, G
    Wellens, E
    Monting, JS
    Schaefer, HE
    Zeiher, AM
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (10) : 2218 - 2224